Multiple myeloma diagnostic criteria: Difference between revisions
Jump to navigation
Jump to search
Sergekorjian (talk | contribs) Created page with "__NOTOC__ {{Multiple myeloma}} {{CMG}} ==Overview== ==Diagnostic Criteria== In November 2014, the International Myeloma Working Group (IMWG) updated the criteria for the diag..." |
Sergekorjian (talk | contribs) |
||
| Line 6: | Line 6: | ||
==Diagnostic Criteria== | ==Diagnostic Criteria== | ||
In November 2014, the International Myeloma Working Group (IMWG) updated the criteria for the diagnosis of multiple myeloma (MM) to include novel validated biomarkers that are associated with the development of CRAB features (hypercalcaemia, renal failure, anaemia, and bone lesions). The update also clarified the underlying laboratory and radiographic findings of CRAB features as well as the histological and monoclonal protein requirements for the disease diagnosis. | In November 2014, the International Myeloma Working Group (IMWG) updated the criteria for the diagnosis of multiple myeloma (MM) to include novel validated biomarkers that are associated with the development of CRAB features (hypercalcaemia, renal failure, anaemia, and bone lesions). The update also clarified the underlying laboratory and radiographic findings of CRAB features as well as the histological and monoclonal protein requirements for the disease diagnosis. | ||
===Revised Criteria for the Diagnosis of Multiple Myeloma=== | |||
{|cquote| | {|cquote| | ||
≥10% clonal expansion of bone marrow plasma cells '''or''' biopsy-proven bony or extramedullary plasmacytoma and one or more of the following features: | '''≥10% clonal expansion of bone marrow plasma cells '''or''' biopsy-proven bony or extramedullary plasmacytoma and one or more of the following features:''' | ||
* Evidence of end organ damage that can be attributed to the underlying plasma cell proliferative disorder: | * Evidence of end organ damage that can be attributed to the underlying plasma cell proliferative disorder: | ||
| Line 21: | Line 22: | ||
|} | |} | ||
===Smouldering Multiple Myeloma=== | ===Criteria for the Diagnosis of Smouldering Multiple Myeloma=== | ||
{|cquote| | {|cquote| | ||
Both criteria must be met: | Both criteria must be met: | ||
Revision as of 17:31, 3 November 2014
|
Multiple myeloma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Multiple myeloma diagnostic criteria On the Web |
|
American Roentgen Ray Society Images of Multiple myeloma diagnostic criteria |
|
Risk calculators and risk factors for Multiple myeloma diagnostic criteria |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Diagnostic Criteria
In November 2014, the International Myeloma Working Group (IMWG) updated the criteria for the diagnosis of multiple myeloma (MM) to include novel validated biomarkers that are associated with the development of CRAB features (hypercalcaemia, renal failure, anaemia, and bone lesions). The update also clarified the underlying laboratory and radiographic findings of CRAB features as well as the histological and monoclonal protein requirements for the disease diagnosis.
Revised Criteria for the Diagnosis of Multiple Myeloma
≥10% clonal expansion of bone marrow plasma cells or biopsy-proven bony or extramedullary plasmacytoma and one or more of the following features:- Evidence of end organ damage that can be attributed to the underlying plasma cell proliferative disorder:
- Hypercalcemia: serum calcium >0·25 mmol/L (>1 mg/dL) higher than the upper limit of normal or >2·75 mmol/L (>11 mg/dL)
- Renal insufficiency: creatinine clearance <40 mL per min† or serum creatinine>177 μmol/L (>2 mg/dL)
- Anemia: hemoglobin value of >20 g/L below the lower limit of normal, or a hemoglobin value <100 g/L
- Bone lesion: one or more osteolytic lesions on skeletal radiography, CT, or PET-CT
- Any one or more of the following biomarkers of malignancy:
- Clonal bone marrow plasma cell percentage ≥60%
- Involved:uninvolved serum free light chain ratio ≥100
- >1 focal lesions on MRI studies
Criteria for the Diagnosis of Smouldering Multiple Myeloma
Both criteria must be met:- Serum monoclonal protein (IgG or IgA) ≥30 g/L or urinary monoclonal protein ≥500 mg per 24 h and/or clonal bone marrow plasma cells 10–60%
- Absence of myeloma-defining events or amyloidosis